Clinical observation of azacitidine combined with CAG regimen in reinduction treatment of pediatric relapsed/refractory acute myeloid leukemia
10.3760/cma.j.cn115356-20210329-00061
- VernacularTitle:阿扎胞苷联合CAG方案再诱导治疗儿童复发难治急性髓系白血病临床观察
- Author:
Yongzhi ZHENG
1
;
Hao ZHENG
;
Jianda HU
Author Information
1. 福建医科大学附属协和医院小儿血液科 福建省血液病研究所 福建省血液病学重点实验室，福州 350001
- Keywords:
Leukemia, myeloid, acute;
Child;
Antineoplastic combined chemotherapy protocols;
Azacitidine
- From:
Journal of Leukemia & Lymphoma
2021;30(8):470-474
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of azacitidine combined with CAG (cytarabine + aclacinomycin + granulocyte colony-stimulating factor) regimen in reinduction treatment of pediatric relapsed/refractory acute myeloid leukemia (AML) patients.Methods:The clinical data of 3 pediatric patients with relapsed/refractory AML treated with azacitidine combined with CAG regimen reinduction in Fujian Medical University Union Hospital between November 2018 and October 2019 were retrospectively analyzed, and the efficacy, prognosis and adverse reactions were also analyzed.Results:Among 3 patients, 2 cases were relapsed AML (relapse time began 18 months and 8 months after treatment started, respectively), and 1 case was refractory AML (cannot achieve complete remission after 2 courses of standard chemotherapy). After 2 courses of azacitidine combined with CAG regimen reinduction, 2 cases achieved complete remission, and 1 case achieved partial remission. And then they all underwent hematopoietic stem cell transplantation (HSCT) and had leukemia-free survival after 16-21 months follow-up (time from the first azacitidine combined with CAG reinduction). Except for hematological adverse reactions and infection, azacitidine did not increase other adverse effects.Conclusions:Azacitidine combined with CAG regimen in reinduction treatment of pediatric relapsed/refractory AML has a higher remission rate and safety, and patients undergoing timely bridging HSCT may have a good prognosis.
